Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > LATEST
LATEST
-
REGULATORY MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
March 4, 2024
-
BUSINESS Shionogi, Osaka University Set Up Joint Research Lab on Long COVID
March 4, 2024
-
BUSINESS Shionogi Healthcare Launches OTC Version of Mucodyne
March 4, 2024
-
REGULATORY Japan’s Revised Drug Distribution Guidelines Take Effect
March 4, 2024
-
BUSINESS Taiho Picks Up Rights to China Pharma’s Lung Cancer Drug
March 4, 2024
-
REGULATORY PMDA Reviewing Safety Risks for 4 CAR-T Therapies and More
March 4, 2024
-
BUSINESS Moderna Japan Taps Kazumasa Nagayama as New President
March 4, 2024
-
REGULATORY Generic Mergers, Product Consolidations Unlikely to Pose Antitrust Issue: FTC Official
March 1, 2024
-
BUSINESS Drugstore Chains Tsuruha and Welcia to Merge, Eye Definite Pact by 2027-End
March 1, 2024
-
BUSINESS FoundationOne Approved as CDx for Retevmo in Japan: Chugai
March 1, 2024
-
BUSINESS MSD Files Keytruda Plus Chemoradiotherapy for Cervical Cancer in Japan
March 1, 2024
-
REGULATORY Chugai’s PNH Med, Takeda’s cTTP Therapy Now in Line for Japan Approval
March 1, 2024
-
REGULATORY Hospitals, Pharmacies Must Also Join Effort in Improving Drug Distribution: Expert Panel Member
February 29, 2024
-
REGULATORY MHLW Sets Out to Beef Up Inspector Skills with Nationwide Sharing of GMP Reports
February 29, 2024
-
BUSINESS Otsuka, AN Ventures Hook Up on US$30 Million Investment
February 29, 2024
-
BUSINESS Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
-
BUSINESS Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
-
BUSINESS Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
-
REGULATORY Health Minister Reaffirms April Start of New Drug Shortage Reporting Scheme
February 28, 2024
-
BUSINESS Towa to Roll Out New WPP Strategy to Maintain NHI Prices of Key Medicines
February 28, 2024
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…